Lexicon Pharmaceuticals, Inc.

LXRX

US5288723027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:00:00 2024-11-29 pm EST			5-day change	1st Jan Change
0.8037 ^USD	-0.15%		-6.91%	-47.47%

Nov. 26	Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain	CI
Nov. 22	Sector Update: Health Care Stocks Edge Higher Late Afternoon	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain	Nov. 26	CI
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Nov. 22	MT
Sector Update: Health Care	Nov. 22	MT
HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating	Nov. 22	MT
Lexicon Pharmaceuticals to Cut 60% of Workforce	Nov. 22	MT
Lexicon Pharmaceuticals, Inc. - Special Call	Nov. 22
Lexicon Pharmaceuticals, Inc. Announces Board Changes	Nov. 20	CI
Lexicon Pharmaceuticals, Inc., Q3 2024 Earnings Call, Nov 12, 2024	Nov. 12
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q3 Revenue $1.7M	Nov. 12	MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Lexicon Pharmaceuticals, Inc. Publishes Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People with Type 1 Diabetes and Chronic Kidney Disease	Nov. 05	CI
Lexicon Pharmaceuticals, Inc. to Present Preclinical in Vivo Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss	Nov. 04	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Nov. 01	MT
Top Midday Decliners	Nov. 01	MT
Wall Street Set to Open Higher Friday; Unemployment Rate Unchanged at 4.1%	Nov. 01	MT
Lexicon Pharmaceuticals Says FDA Panel Opposes Zynquista for Type 1 Diabetes and Kidney Disease	Nov. 01	MT
Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote	Nov. 01	DJ
Top Premarket Decliners	Nov. 01	MT
US Futures Rise Pre-Bell as Investors Await Key Employment, Manufacturing Data	Nov. 01	MT
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update	Oct. 31	DJ
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista	Oct. 31	DJ
Lexicon Pharmaceuticals, Inc. Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease	Oct. 31	CI
Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista	Oct. 31	DJ
Lexicon Pharmaceuticals, Inc. Announces Completion of Screening in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain	Oct. 22	CI
Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal	Oct. 16	MT

Chart Lexicon Pharmaceuticals, Inc.

Duration

Period

LXRX: Dynamic Chart

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.

Employees

285

Sector

Biotechnology & Medical Research

Calendar

2024-12-03 - Piper Sandler Healthcare Conference

More about the company